within Pharmacolibrary.Drugs.ATC.V;

model V09IX05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1.0,
    Cl             = 0.0025,
    adminDuration  = 600,
    adminMass      = 0.185,
    adminCount     = 1,
    Vd             = 0.0025,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Fluorodopa (18F), also known as 6-[18F]fluoro-L-dopa, is a radiolabeled analog of the amino acid L-dopa used primarily as a diagnostic imaging agent in positron emission tomography (PET) for the assessment of presynaptic dopaminergic function, especially in the diagnosis and evaluation of Parkinson’s disease and related movement disorders. It is not used as a therapeutic drug, but as a diagnostic tool approved in several countries for PET imaging.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers and patients undergoing PET imaging studies.</p><h4>References</h4><ol><li><p>Cumming, P, et al., &amp; McGeer, EG (1987). Altered metabolism of [18F]-6-fluorodopa in the hooded rat following inhibition of catechol-O-methyltransferase with U-0521. <i>Biochemical pharmacology</i> 36(15) 2527–2531. DOI:<a href=&quot;https://doi.org/10.1016/0006-2952(87)90526-0&quot;>10.1016/0006-2952(87)90526-0</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3111485/&quot;>https://pubmed.ncbi.nlm.nih.gov/3111485</a></p></li><li><p>Wahl, L, &amp; Nahmias, C (1996). Modeling of fluorine-18-6-fluoro-L-Dopa in humans. <i>Journal of nuclear medicine : official publication, Society of Nuclear Medicine</i> 37(3) 432–437. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8772639/&quot;>https://pubmed.ncbi.nlm.nih.gov/8772639</a></p></li><li><p>Hammerstad, JP, et al., &amp; Calne, DB (1993). The transport of L-6-fluorodopa and its metabolites from blood to cerebrospinal fluid and brain. <i>Annals of neurology</i> 34(4) 603–608. DOI:<a href=&quot;https://doi.org/10.1002/ana.410340415&quot;>10.1002/ana.410340415</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8215248/&quot;>https://pubmed.ncbi.nlm.nih.gov/8215248</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end V09IX05;
